Surgical Science Sweden AB
STO:SUS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
113.7
193.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Surgical Science Sweden AB
Cash & Cash Equivalents
Surgical Science Sweden AB
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Surgical Science Sweden AB
STO:SUS
|
Cash & Cash Equivalents
kr666.3m
|
CAGR 3-Years
29%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
Elekta AB (publ)
STO:EKTA B
|
Cash & Cash Equivalents
kr2.8B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
CellaVision AB
STO:CEVI
|
Cash & Cash Equivalents
kr137.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
9%
|
|
|
Getinge AB
STO:GETI B
|
Cash & Cash Equivalents
kr2.7B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Cash & Cash Equivalents
kr923m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
S
|
Stille AB
STO:STIL
|
Cash & Cash Equivalents
kr97.9m
|
CAGR 3-Years
45%
|
CAGR 5-Years
20%
|
CAGR 10-Years
52%
|
|
Surgical Science Sweden AB
Glance View
Surgical Science Sweden AB engages in the development of simulators for laparoscopic medical training. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-06-19. The systems comprise LapSim, EndoSim and TeamSim trainings. Each training combine graphics and cognitive instruction, imply navigation on touch screens and feature tactile feedback technology. The LapSim trainings consist of laparoscopic exercises that range from basic navigation to advanced suturing, the EndoSim endoscopic exercises range from functions of the scope handle and tube, to loop reduction. The TeamSim comprises procedure modules to train in a real world operation room environment and helps to build team communication skills in crisis and routine situations. The training systems are used by medical training centers and institutes worldwide for practice, validation and certification of students, surgeons, and medical doctors.
See Also
What is Surgical Science Sweden AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
666.3m
SEK
Based on the financial report for Sep 30, 2024, Surgical Science Sweden AB's Cash & Cash Equivalents amounts to 666.3m SEK.
What is Surgical Science Sweden AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
58%
Over the last year, the Cash & Cash Equivalents growth was 10%. The average annual Cash & Cash Equivalents growth rates for Surgical Science Sweden AB have been 29% over the past three years , 58% over the past five years .
You don't have any saved screeners yet
